Fierce 50 for 2026 Spotlights Bets on "Undruggable" Targets and Public Trust

The Fierce 50 of 2026 is out, and the list functions less as an award ceremony than as a signal of where the healthcare and life sciences industries are placing their bets. Fierce Editor-in-Chief Ayla Ellison unpacked several of the standout stories in a recent episode of the "Podnosis" podcast, and the throughline across the honorees is a shift toward tackling problems long considered intractable, whether that's a cancer mutation, a public trust deficit, or the basic mechanics of health literacy.

This year's roster includes scientists, physicians, public health leaders, patient advocates and organizations. Some are developing new medicines. Others are closing gaps in access and representation, rethinking disease prevention, or finding new channels to deliver public health information to the communities that need it most.

The most commercially significant story on the list involves Revolution Medicines and its work on RAS, a cancer target that drug developers avoided for decades because it was considered biologically undruggable. That characterization has defined an entire category of oncology research since the 1980s, when RAS mutations were first linked to a substantial share of human cancers. Revolution Medicines' inclusion in the Fierce 50 reflects a broader industry pattern: companies willing to spend years and significant capital chasing targets that other firms have written off tend to capture outsized attention, and sometimes outsized returns, if the science holds up.

David Baker, Ph.D., also earned recognition for his protein-design work, a field that has moved from academic curiosity to a genuine platform technology over the past several years. Protein design sits upstream of drug discovery, and progress there tends to ripple through the pipelines of companies building on the underlying science.

Public Health's Retention Problem

Michael Osterholm, Ph.D., made the list for a decision that says as much about the state of public health leadership as it does about him individually: he chose to delay his own retirement from the field. Ellison's podcast frames this as notable precisely because so many experienced public health voices have exited the profession since 2020, taking institutional knowledge and, in some cases, public credibility with them. Osterholm staying on is presented less as a personal milestone and more as a data point about a sector still struggling to retain senior talent after a punishing few years.

That retention question connects directly to the communication and trust theme running through several other honorees. Lisa Fitzpatrick, M.D., Hip Hop Public Health, Eric Topol, M.D., and Mary Owen, M.D., were all recognized for work that reframes how health information reaches the public and how equity gets built into that delivery. Fitzpatrick and Hip Hop Public Health approach the trust problem through cultural relevance and community-rooted messaging rather than top-down public health campaigns. Topol's inclusion reflects his continued focus on translating complex medical evidence into terms patients and clinicians alike can act on. Owen's work centers health equity, an area where the gap between stated industry priorities and measurable outcomes has remained stubbornly wide.

None of these honorees operate in isolation from each other. A cancer drug targeting a previously undruggable mutation is only as valuable as the health system's ability to identify eligible patients and get them into care, which depends on the kind of literacy and trust-building work Fitzpatrick and Owen are doing. Protein design platforms like Baker's only translate into patient benefit if public health infrastructure, the kind Osterholm has spent a career defending, can support deployment at scale. The Fierce 50 list, in aggregate, reads as an argument that scientific breakthrough and public trust infrastructure are two halves of the same investment thesis.

The Bottom Line

For investors and industry watchers, the practical takeaway from this year's list is less about any single honoree and more about pattern recognition. Companies and individuals rewarded with Fierce 50 recognition tend to share a willingness to work on problems with long time horizons and uncertain payoffs, whether that's a decade-plus RAS drug development program or a public health communication strategy built around cultural trust rather than institutional authority.

Revolution Medicines' RAS program is the clearest example of a binary, high-reward bet within this year's cohort. Undruggable targets that become druggable tend to create durable competitive moats, since the scientific difficulty that kept competitors away for decades doesn't evaporate once one company cracks the code. That said, RAS-targeted therapeutics remain in various stages of clinical development industry-wide, and the source material here doesn't specify trial phases or data readouts for Revolution Medicines specifically, so investors should treat this as a thesis to monitor rather than a confirmed catalyst.

The softer signal from this year's list, the emphasis on health literacy, equity and public trust, matters more for long-duration healthcare investors than it might initially appear. Distribution and adoption friction, not just clinical efficacy, increasingly determines commercial outcomes for new therapeutics and public health interventions alike. Honorees like Fitzpatrick, Hip Hop Public Health and Owen are effectively working the demand side of that equation. Companies and investors focused purely on the supply side, meaning drug development and protein engineering, ignore that demand-side friction at their own risk. The 2026 Fierce 50 is a reminder that in healthcare, the hardest problems to solve are rarely just scientific ones.